[go: up one dir, main page]

NO20044826L - Pyrrolidinderivater - Google Patents

Pyrrolidinderivater

Info

Publication number
NO20044826L
NO20044826L NO20044826A NO20044826A NO20044826L NO 20044826 L NO20044826 L NO 20044826L NO 20044826 A NO20044826 A NO 20044826A NO 20044826 A NO20044826 A NO 20044826A NO 20044826 L NO20044826 L NO 20044826L
Authority
NO
Norway
Prior art keywords
pyrrolidine
antagonists
therapy
formula
preparation
Prior art date
Application number
NO20044826A
Other languages
English (en)
Inventor
Maria Prat Quinones
Maria Dollors Fernandez Forner
Original Assignee
Almirall Prodesfarma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almirall Prodesfarma Ag filed Critical Almirall Prodesfarma Ag
Publication of NO20044826L publication Critical patent/NO20044826L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Nye pyrrolidinderivater som har den kjemiske strukturen av formel (I) er vist; så vel som fremgangsmåter for deres fremstilling, farmasøytiske sammensetninger omfattende dem og deres anvendelse i terapi som antagonister av M3-muskarine reseptorer.
NO20044826A 2002-04-16 2004-11-05 Pyrrolidinderivater NO20044826L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200200889A ES2206021B1 (es) 2002-04-16 2002-04-16 Nuevos derivados de pirrolidinio.
PCT/EP2003/003786 WO2003087094A2 (en) 2002-04-16 2003-04-11 Pyrrolidinium derivatives as antagonists of m3 muscarinic receptors

Publications (1)

Publication Number Publication Date
NO20044826L true NO20044826L (no) 2005-01-14

Family

ID=29225796

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20044826A NO20044826L (no) 2002-04-16 2004-11-05 Pyrrolidinderivater

Country Status (21)

Country Link
US (2) US7192978B2 (no)
EP (1) EP1497284A2 (no)
CN (1) CN100548978C (no)
AR (1) AR039412A1 (no)
AU (1) AU2003233967B2 (no)
BR (1) BR0309167A (no)
CA (1) CA2482536A1 (no)
CO (1) CO5611106A2 (no)
ES (1) ES2206021B1 (no)
IL (1) IL164522A0 (no)
MX (1) MXPA04010076A (no)
MY (1) MY137535A (no)
NO (1) NO20044826L (no)
NZ (1) NZ535884A (no)
PE (1) PE20040409A1 (no)
RU (1) RU2320657C2 (no)
TW (1) TW200403237A (no)
UA (1) UA79283C2 (no)
UY (1) UY27760A1 (no)
WO (1) WO2003087094A2 (no)
ZA (1) ZA200408335B (no)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
TW200519106A (en) 2003-05-02 2005-06-16 Novartis Ag Organic compounds
AR044851A1 (es) 2003-06-24 2005-10-05 Novartis Ag Compuestos heterociclicos, antagonistas del receptor m3 muscarinico
US20050026887A1 (en) * 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a steroid
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
JP2007530451A (ja) * 2004-03-11 2007-11-01 グラクソ　グループ　リミテッド 新規ｍ３ムスカリン性アセチルコリン受容体アンタゴニスト
UY28871A1 (es) 2004-04-27 2005-11-30 Glaxo Group Ltd Antagonistas del receptor de acetilcolina muscarinico
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
ES2257152B1 (es) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
SI1765404T1 (sl) * 2004-05-31 2009-04-30 Almirall Lab Kombinacije, ki obsegajo antimuskarinska sredstva in beta-adrenergične agoniste
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0428416D0 (en) * 2004-12-24 2005-02-02 Novartis Ag Organic compounds
GB0428418D0 (en) * 2004-12-24 2005-02-02 Novartis Ag Organic compounds
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
TW200722418A (en) * 2005-04-20 2007-06-16 Astrazeneca Ab Novel compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
JP2009504624A (ja) * 2005-08-08 2009-02-05 アージェンタ ディスカバリー リミテッド ビシクロ［２．２．１］ヘプタ−７−イルアミン誘導体およびその使用
PT2532679T (pt) 2005-10-21 2017-07-18 Novartis Ag Anticorpos humanos contra il13 e utilizações terapêuticas
EP1971572A1 (en) * 2005-12-16 2008-09-24 Argenta Discovery Limited Cyclic amine derivatives and their uses
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
BRPI0710573A2 (pt) 2006-04-21 2012-02-28 Novartis Ag compostos orgánicos, usos e processos para a preparação dos referidos compostos, bem como composição farmacêutica compreendendo os mesmos
ES2298049B1 (es) 2006-07-21 2009-10-20 Laboratorios Almirall S.A. Procedimiento para fabricar bromuro de 3(r)-(2-hidroxi-2,2-ditien-2-ilacetoxi)-1-(3-fenoxipropil)-1-azoniabiciclo (2.2.2) octano.
CA2664378A1 (en) 2006-09-29 2008-04-03 Novartis Ag Pyrazolopyrimidines as pi3k lipid kinase inhibitors
TW200825084A (en) 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521
WO2008075006A1 (en) * 2006-12-19 2008-06-26 Astrazeneca Ab Piperldinum compounds for treatment of obstructive pulmonary diseases ( copd)
BRPI0720799A2 (pt) 2007-01-10 2014-03-11 Irm Llc Compostos e composições como inibidores de protease de ativação de canal.
WO2008096094A1 (en) * 2007-02-06 2008-08-14 Argenta Discovery Ltd. Bicyclor[2.2.1]hept-7-ylamine derivatives as muscarinic m3 receptor modulators
AU2008218962B2 (en) * 2007-02-23 2013-03-14 Theravance Biopharma R&D Ip, Llc Quaternary ammonium diphenylmethyl compounds useful as muscarinic receptor antagonists
WO2008135557A1 (en) 2007-05-07 2008-11-13 Novartis Ag Organic compounds
CA2697752C (en) * 2007-09-07 2016-01-26 Theravance, Inc. Guanidine-containing compounds useful as muscarinic receptor antagonists
CA2608561A1 (en) * 2007-10-29 2009-04-29 Carl Paluszkiewicz Motorcycle wind deflector accessory support
CN101939054B (zh) 2007-12-10 2014-10-29 诺华股份有限公司 有机化合物
WO2009079392A1 (en) 2007-12-14 2009-06-25 Theravance, Inc. Amidine-containing compounds useful as muscarinic receptor antagonists
EP2231642B1 (en) 2008-01-11 2013-10-23 Novartis AG Pyrimidines as kinase inhibitors
EP2100598A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
US8268834B2 (en) 2008-03-19 2012-09-18 Novartis Ag Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
MX2010012189A (es) 2008-05-13 2011-03-02 Astrazeneca Ab Derivados de quinuclidina como antagonistas del receptor m3 muscarinico.
EP2300010B1 (en) 2008-06-10 2015-03-04 Novartis AG Pyrazine derivatives as epithelial sodium channel blockers
WO2010088335A1 (en) 2009-01-29 2010-08-05 Novartis Ag Substituted benzimidazoles for the treatment of astrocytomas
CN102388021B (zh) 2009-04-09 2015-02-18 诺华股份有限公司 吡咯烷鎓盐的制备方法
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
AU2010283806A1 (en) 2009-08-12 2012-03-01 Novartis Ag Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
BR112012003709B1 (pt) 2009-08-17 2021-05-18 Intellikine Llc compostos heterocíclicos e usos dos mesmos
MX2012002179A (es) 2009-08-20 2012-03-16 Novartis Ag Compuestos heterociclicos de oxima.
CA2777245A1 (en) 2009-10-22 2011-04-28 Vertex Pharmaceuticals Incorporated Compositions for treatment of cystic fibrosis and other chronic diseases
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
WO2012107500A1 (en) 2011-02-10 2012-08-16 Novartis Ag [1, 2, 4] triazolo [4, 3 -b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
JP5808826B2 (ja) 2011-02-23 2015-11-10 インテリカイン， エルエルシー 複素環化合物およびその使用
CA2828219A1 (en) 2011-02-25 2012-08-30 Irm Llc Pyrazolo [1,5-a] pyridines as trk inhibitors
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
UY34305A (es) 2011-09-01 2013-04-30 Novartis Ag Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar
UY34329A (es) 2011-09-15 2013-04-30 Novartis Ag Compuestos de triazolopiridina
JP6165733B2 (ja) 2011-09-16 2017-07-19 ノバルティス アーゲー Ｎ−置換ヘテロシクリルカルボキサミド類
WO2013038386A1 (en) 2011-09-16 2013-03-21 Novartis Ag Heterocyclic compounds for the treatment of cystic fibrosis
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
CN104363914A (zh) 2011-11-23 2015-02-18 因特利凯有限责任公司 使用mTOR抑制剂的增强的治疗方案
US8809340B2 (en) 2012-03-19 2014-08-19 Novartis Ag Crystalline form
CN110507654A (zh) 2012-04-03 2019-11-29 诺华有限公司 有酪氨酸激酶抑制剂的组合产品和其应用
WO2014014698A2 (en) 2012-07-16 2014-01-23 Barry University Inc. Bitopic muscarinic agonists and antagonists and methods of synthesis and use thereof
CN103965178B (zh) * 2013-02-06 2018-03-02 中国药科大学 作为m3毒蕈碱性受体拮抗剂的吡咯烷鎓衍生物及其在制药中的用途
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
WO2014151147A1 (en) 2013-03-15 2014-09-25 Intellikine, Llc Combination of kinase inhibitors and uses thereof
TW201605450A (zh) 2013-12-03 2016-02-16 諾華公司 Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
CA2945212A1 (en) 2014-04-24 2015-10-29 Novartis Ag Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
BR112016024484A2 (pt) 2014-04-24 2017-08-15 Novartis Ag derivados de aminopiridina como inibidores de fosfatidilinositol 3-quinase
CN106458966B (zh) 2014-04-24 2019-05-07 诺华股份有限公司 作为磷脂酰肌醇3-激酶抑制剂的吡嗪衍生物
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
CA2954862A1 (en) 2014-07-31 2016-02-04 Novartis Ag Combination therapy
CN105085355B (zh) * 2015-06-25 2017-11-14 御盛隆堂药业有限责任公司 一种取代的吡咯烷羧酸酯类化合物及其制备方法和应用
JP6770005B2 (ja) 2016-02-10 2020-10-14 住友化学株式会社 １−メチルピロリジン−３−オールの製造方法
WO2018026869A1 (en) 2016-08-02 2018-02-08 Dermira, Inc. Processes for making, and methods of using, glycopyrronium compounds
CN113891744A (zh) 2019-06-10 2022-01-04 诺华股份有限公司 用于治疗cf、copd和支气管扩张的吡啶和吡嗪衍生物
PE20220346A1 (es) 2019-08-28 2022-03-14 Novartis Ag Derivados de 1,3-fenil heteroarilo sustituidos y su uso en el tratamiento de enfermedades
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法
CN116514833A (zh) * 2023-04-28 2023-08-01 南京联智医药科技有限公司 一种氘代物及其合成方法和医药用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2956062A (en) * 1959-02-26 1960-10-11 Robins Co Inc A H Esters of amino alcohols
US3301869A (en) * 1960-05-16 1967-01-31 Robins Co Inc A H Methobromide and hydrochloride of 1-ethyl-3-pyrrolidyl benzilate
GB1219606A (en) * 1968-07-15 1971-01-20 Rech S Et D Applic Scient Soge Quinuclidinol derivatives and preparation thereof
FR2155927A1 (en) * 1971-10-15 1973-05-25 Synthelabo 1-phenylcyclo hexane carboxylic acid esters - with antispasmodic and anticholinergic activity
JPS5679688A (en) * 1979-12-04 1981-06-30 Ota Seiyaku Kk 4-acyloxy-1- 1,3-dioxoran-2-ylmethyl piperidine derivative and its production
AU7145996A (en) * 1995-10-13 1997-04-30 Banyu Pharmaceutical Co., Ltd. Substituted heteroaromatic derivatives
DK0937041T3 (da) 1996-11-11 2003-08-11 Christian R Noe Anvendelse af et farmaceutisk egnet salt af (3R,2'R)-3-[(cyclopentil-hydroxyphenylacetyl)oxyl]-1,1-dimethyl-pyrrolidinium til fremstilling af et lægemiddel
US6613795B2 (en) * 1996-11-11 2003-09-02 Christian Noe Enantiomerically pure basic arylcycloalkylhydroxycarboxylic esters, processes for their preparation and their use in medicaments
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
CA2411782A1 (en) * 2000-06-30 2002-01-17 Cochlear Limited Cochlear implant
WO2002004402A1 (fr) * 2000-07-11 2002-01-17 Banyu Pharmaceutical Co., Ltd. Derives d'ester
US7174126B2 (en) * 2002-05-03 2007-02-06 Time Warner Interactive Video Group Inc. Technique for effectively accessing programming listing information in an entertainment delivery system

Also Published As

Publication number Publication date
CO5611106A2 (es) 2006-02-28
ES2206021A1 (es) 2004-05-01
WO2003087094A3 (en) 2004-03-18
AU2003233967A1 (en) 2003-10-27
US7192978B2 (en) 2007-03-20
MXPA04010076A (es) 2004-12-13
WO2003087094A2 (en) 2003-10-23
IL164522A0 (en) 2005-12-18
BR0309167A (pt) 2005-01-25
ZA200408335B (en) 2005-11-02
UY27760A1 (es) 2003-11-28
RU2004133371A (ru) 2005-08-10
CN100548978C (zh) 2009-10-14
PE20040409A1 (es) 2004-07-14
US20070129420A1 (en) 2007-06-07
TW200403237A (en) 2004-03-01
ES2206021B1 (es) 2005-08-01
CN1662527A (zh) 2005-08-31
US20050282875A1 (en) 2005-12-22
NZ535884A (en) 2007-11-30
CA2482536A1 (en) 2003-10-23
AU2003233967B2 (en) 2009-08-06
MY137535A (en) 2009-02-27
EP1497284A2 (en) 2005-01-19
UA79283C2 (en) 2007-06-11
AR039412A1 (es) 2005-02-16
RU2320657C2 (ru) 2008-03-27

Similar Documents

Publication Publication Date Title
NO20044826L (no) Pyrrolidinderivater
NO20062335L (no) Nye diazaspiroalkaner og deres anvendelse i behandlingen av CCR8 medierte sykdommer
NO20060001L (no) Nye P2X7-reseptorantagonister og deres anvendelse
NO20050164L (no) Nye quinuklidin-amid-derivater
NO20061839L (no) Benzimidazolderivater, sammensetninger inneholdende dem, fremstilling derav, og anvendelse derav
NO20065904L (no) Terapeutiske forbindelser
NO20045486L (no) Nye forbindelser og deres anvendelse
NO20064166L (no) Utvalgte CGRP-antagonister, deres fremstilling og deres anvendelse som medikanmenter
NO20052496L (no) Selekterte CGRP antagonister, fremgangsmater for fremstilling derav og anvendelse derav som medikamenter.
NO20054329L (no) Adamantanderivater, fremgangsmater for deres fremstilling og farmasoytiske sammensetninger som innbefatter slike
NO20060147L (no) Benzimidazolderivater, sammensetninger som inneholder slike, fremstilling derav og anvendelse derav
NO20052493L (no) Selekterte CGRP antagonister, fremgangsmater for fremstilling derav og deres anvendelse som farmasoytiske sammensetninger.
NO20080670L (no) Substituerte piperaziner som metabotrofiske glutamatreseptorantagonister
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
NO20071140L (no) Nye piperidinderivater som histamin H3 reseptorligander for behandling av depresjon
NO20071108L (no) Nye 4-benzylidenpiperidinderivater
NO20055977L (no) Nye benzimidazolderivater
NO20081001L (no) Derivater av karboksamid som antagonister for muskarinisk reseptor
NO20060146L (no) Benzimidazolderivater, sammensetninger som inneholder slike, fremstilling derav og anvendelse derav
NO20070570L (no) Forbindelser.
NO20062900L (no) Nye forbindelser
SE0402762D0 (sv) Indazole sulphonamide derivatives
NO20061981L (no) Arylindenopyridiner og arylindenopyridiner og deres anvendelse som adenosin A2A reseptoragonist
ATE386725T1 (de) Heterocyclylverbindungen
NO20072089L (no) Benzimidazolderivater, sammensetninger som inneholder dem, fremstilling derav og anvendelse derav

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application